111 related articles for article (PubMed ID: 17287635)
1. Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism.
Castro DJ; Díaz G; Martí D; Escobar C; Ortega J; García-Rull S; Picher J; Sueiro A
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):173-7. PubMed ID: 17287635
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
[TBL] [Abstract][Full Text] [Related]
3. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
4. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism.
Beckman JA; Dunn K; Sasahara AA; Goldhaber SZ
Thromb Haemost; 2003 Jun; 89(6):953-8. PubMed ID: 12783106
[TBL] [Abstract][Full Text] [Related]
6. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
[TBL] [Abstract][Full Text] [Related]
8. [Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
Heidenreich C; Hohmann V; Bramlage P
Med Klin (Munich); 2009 Jan; 104(1):20-7. PubMed ID: 19142593
[TBL] [Abstract][Full Text] [Related]
9. Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
Hacobian M; Shetty R; Niles CM; Gerhard-Herman M; Vallurupalli N; Baroletti S; McKean SC; Sonis J; Parasuraman S; Kosowsky JM; Goldhaber SZ
Clin Appl Thromb Hemost; 2010 Feb; 16(1):21-5. PubMed ID: 19147527
[TBL] [Abstract][Full Text] [Related]
10. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
11. The prophylaxis of medical patients for thromboembolism pilot study.
Lederle FA; Sacks JM; Fiore L; Landefeld CS; Steinberg N; Peters RW; Eid AA; Sebastian J; Stasek JE; Fye CL
Am J Med; 2006 Jan; 119(1):54-9. PubMed ID: 16431185
[TBL] [Abstract][Full Text] [Related]
12. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
de Groot MR; Njo TL; van Marwijk Kooy M; Büller HR
Clin Lab; 2000; 46(11-12):575-81. PubMed ID: 11109505
[TBL] [Abstract][Full Text] [Related]
13. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
[TBL] [Abstract][Full Text] [Related]
14. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Deitcher SR; Kessler CM; Merli G; Rigas JR; Lyons RM; Fareed J;
Clin Appl Thromb Hemost; 2006 Oct; 12(4):389-96. PubMed ID: 17000884
[TBL] [Abstract][Full Text] [Related]
15. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
[TBL] [Abstract][Full Text] [Related]
16. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Aujesky D; Roy PM; Verschuren F; Righini M; Osterwalder J; Egloff M; Renaud B; Verhamme P; Stone RA; Legall C; Sanchez O; Pugh NA; N'gako A; Cornuz J; Hugli O; Beer HJ; Perrier A; Fine MJ; Yealy DM
Lancet; 2011 Jul; 378(9785):41-8. PubMed ID: 21703676
[TBL] [Abstract][Full Text] [Related]
17. Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery.
Kistler U; Kramers-de Quervain I; Munzinger U; Kucher N
Thromb Haemost; 2008 Jun; 99(6):1049-52. PubMed ID: 18521507
[TBL] [Abstract][Full Text] [Related]
18. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Omran H; Hammerstingl C; Paar WD;
Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
[TBL] [Abstract][Full Text] [Related]
19. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.
Chong BH; Brighton TA; Baker RI; Thurlow P; Lee CH;
J Thromb Thrombolysis; 2005 Jun; 19(3):173-81. PubMed ID: 16082604
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
